Pirtobrutinib is Used for treating adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy including a BTK inhibitor and a BCL-2 inhibitor. It was first introduced by Loxo Oncology Inc in its drug Jaypirca on Jan 27, 2023.

Pirtobrutinib Patents

Given below is the list of patents protecting Pirtobrutinib, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Jaypirca	US12109193	Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide	Sep 14, 2041	Loxo Oncol
Jaypirca	US10342780	Compounds useful as kinase inhibitors	Dec 16, 2036	Loxo Oncol
Jaypirca	US10464905	Compounds useful as kinase inhibitors	Dec 16, 2036	Loxo Oncol
Jaypirca	US10695323	Compounds useful as kinase inhibitors	Dec 16, 2036	Loxo Oncol
Jaypirca	US10918622	Compounds useful as kinase inhibitors	Dec 16, 2036	Loxo Oncol

Add above patents to watchlist

Pirtobrutinib's Family Patents

Full family tree